XL Laboratories Private Limited

XL Laboratories Private Limited, incorporated on March 16, 2000, is a privately held pharmaceutical company based in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL2000PTC104513. Its authorized and paid-up capital stands at ₹3.00 crore, reflecting a solid financial foundation. The registered office is located at DSM 430-431, DLF Tower, Shivaji Marg, New Delhi, Delhi 110015, India.

As of October 26, 2025, XL Laboratories Private Limited is led by two directors: Ashok Kumar Bhargava and Rahul Bhargava, who have been serving since February 11, 2002, and March 16, 2002, respectively. The company employs over 450 professionals, indicating a robust workforce dedicated to its operations. For more information, the company's official website is xlrem.com.

XL Laboratories Private Limited operates manufacturing facilities in Bhiwadi, Rajasthan, and New Delhi, Delhi. These plants specialize in the production of pharmaceutical formulations, including tablets, hard gelatin capsules, soft gelatin capsules, oral liquids, and sachets. The company holds approvals from various regulatory bodies, such as EU GMP, PIC/s, TGA, and WHO GMP, ensuring compliance with international quality standards.

The leadership team at XL Laboratories Private Limited comprises:

• Ashok Kumar Bhargava: Managing Director, appointed on February 11, 2002.

• Rahul Bhargava: Director, appointed on March 16, 2002.

Under their guidance, the company has expanded its product portfolio and global presence, emphasizing quality and innovation in pharmaceutical manufacturing.

XL Laboratories Private Limited has established a significant presence in regulated markets, including the European Union (EU), United Kingdom (UK), Australia, and Brazil. The company has secured approvals such as EU GMP, TGA (Australia), ANVISA (Brazil), PIC/s, and Thai FDA, facilitating its entry into these markets. These certifications enable XL Laboratories to engage in contract manufacturing and license its intellectual property, with over 25 marketing authorizations in the regulated market space.

In addition to its presence in regulated markets, XL Laboratories Private Limited has expanded its footprint into emerging markets across Africa, Latin America, Southeast Asia, China, Hong Kong, and the Indian subcontinent. The company's in-house Regulatory Department has been instrumental in obtaining more than 600 product registrations globally, including in these regions. This expansion is supported by the company's status as a Star Export House, granted by the Ministry of Commerce, Government of India, for outstanding performance in international markets.

XL Laboratories Private Limited demonstrates a diversified geographic strategy by operating in over 32 countries, including Europe, Southeast Asia, China, Hong Kong, Africa, South America, the Commonwealth of Independent States (CIS), and the Indian subcontinent. This broad geographic reach mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The strategic direction focuses on expanding market access through regulatory approvals and establishing a global presence.

As of the latest available data, XL Laboratories Private Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company has not been subject to any FDA inspections, Form 483 observations, warning letters, or import alerts. This indicates that XL Laboratories has not yet entered the U.S. market or engaged in activities requiring FDA oversight.

XL Laboratories Private Limited holds certifications from the World Health Organization (WHO) Good Manufacturing Practices (GMP) and the European Union (EU) GMP. These certifications affirm the company's adherence to international quality standards in pharmaceutical manufacturing. The company's manufacturing facilities have also secured approvals from the Pharmaceutical Inspection Co-operation Scheme (PIC/s), Therapeutic Goods Administration (TGA) in Australia, and Thai FDA, further demonstrating its commitment to quality and regulatory compliance.

In India, XL Laboratories Private Limited operates under the guidelines of the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with national regulatory requirements. Additionally, XL Laboratories has obtained export No Objection Certificates (NOCs), facilitating its international trade activities. The company's in-house Regulatory Department plays a crucial role in navigating the regulatory landscape and obtaining necessary approvals for both domestic and international markets.

As of the latest available information, XL Laboratories Private Limited has not been subject to any regulatory actions, including Form 483 observations, warning letters, or import alerts from regulatory bodies such as the FDA, WHO, or CDSCO. This suggests that the company maintains a clean regulatory record, reflecting its commitment to compliance and quality standards.

In the pharmaceutical manufacturing sector, XL Laboratories Private Limited faces competition from both domestic and international companies. Key competitors include established Indian pharmaceutical manufacturers and global entities with a presence in the same therapeutic categories. While specific market share data is not available, XL Laboratories' focus on quality, regulatory compliance, and a diversified product portfolio positions it competitively in the market. The company's ability to secure approvals in regulated markets and its extensive global reach are significant competitive advantages.

XL Laboratories Private Limited distinguishes itself through its commitment to quality, as evidenced by its certifications from WHO GMP, EU GMP, PIC/s, TGA, and Thai FDA. The company's in-house Regulatory Department has been instrumental in obtaining over 600 product registrations globally, facilitating its presence in more than 32 countries. Additionally, XL Laboratories' status as a Star Export House, granted by the Ministry of Commerce, Government of India, underscores its outstanding performance in international markets.

XL Laboratories Private Limited's strategic direction focuses on expanding its global footprint through regulatory approvals and market access in both regulated and emerging markets. The company's emphasis on quality manufacturing, supported by various international certifications, positions it to meet the demands of diverse markets. Looking ahead, XL Laboratories aims to leverage its strengths in research and development, regulatory compliance, and global distribution to drive growth and innovation in the pharmaceutical sector.

XL Laboratories Private Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $1.6 million USD across 69 shipments. The company's product portfolio spans four therapeutic categories, with a concentration in Ayurvedic & Herbal Products (43.3%), Lipid & Metabolism (28.4%), and Respiratory & OTC (24.2%). The top five products include Natural ($700K, Rank #5, 2.7% market share), Colchicine ($459K, Rank #10, 2.2% market share), Dextromethorphan ($391K, Rank #10, 2.6% market share), and Melatonin ($68K, Rank #14, 0.7% market share). This diverse product range and consistent export performance indicate reliability and capacity in meeting international demand.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO GMP: Confirms adherence to World Health Organization Good Manufacturing Practices.

• EU GMP: Indicates compliance with European Union Good Manufacturing Practices.

• PIC/s: Affirms alignment with the Pharmaceutical Inspection Co-operation Scheme standards.

• TGA: Validates approval from the Therapeutic Goods Administration in Australia.

• Thai FDA: Indicates approval from the Thai Food and Drug Administration.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting copies directly from XL Laboratories Private Limited.

Importers should undertake the following steps to ensure a thorough evaluation of XL Laboratories Private Limited:

• Verify Certifications: Confirm the validity of WHO GMP, EU GMP, PIC/s, TGA, and Thai FDA certifications.

• Assess Regulatory Compliance: Review the company's compliance history with regulatory bodies such as CDSCO